Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd Feaster

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Clinical Neuropsychologist|April 23, 2011
Visual acuity is associated with performance on visual and non-visual neuropsychological tests in multiple sclerosisH Todd Feaster, Jared M Bruce
Trials|March 24, 2026
Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview studyElizabeth Merikle, Carrie Presnall, Todd Feaster, et al.
Journal of Clinical and Experimental Neuropsychology|December 11, 2014
Speedy eye movements in multiple sclerosis: association with performance on visual and nonvisual cognitive testsBrandon L Roberg, Jared M Bruce, H Todd Feaster, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 10, 2025
Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of SabirnetugRobyn Moxon, Todd Feaster, Gopalan Sethuraman, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Establishing Equivalence of Electronic Clinician-Reported Outcome MeasuresRebecca L M Fuller, Cynthia W McNamara, William R Lenderking, et al.
Psychiatry Research|December 24, 2021
Diversity and disparities in research studies and career trajectories in psychiatryKia Crittenden-Ward, Martina Micaletto, Jennifer Olt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentTodd Feaster, Prajakta Dinesh Mangeshkar, Siew Tin Gan, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
The Journal of Prevention of Alzheimer'S Disease|February 15, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's diseaseErika N Cline, Daniel Antwi-Berko, Karen Sundell, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Clinical Neuropsychologist|April 23, 2011
Visual acuity is associated with performance on visual and non-visual neuropsychological tests in multiple sclerosisH Todd Feaster, Jared M Bruce
Trials|March 24, 2026
Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview studyElizabeth Merikle, Carrie Presnall, Todd Feaster, et al.
Journal of Clinical and Experimental Neuropsychology|December 11, 2014
Speedy eye movements in multiple sclerosis: association with performance on visual and nonvisual cognitive testsBrandon L Roberg, Jared M Bruce, H Todd Feaster, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 10, 2025
Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of SabirnetugRobyn Moxon, Todd Feaster, Gopalan Sethuraman, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Establishing Equivalence of Electronic Clinician-Reported Outcome MeasuresRebecca L M Fuller, Cynthia W McNamara, William R Lenderking, et al.
Psychiatry Research|December 24, 2021
Diversity and disparities in research studies and career trajectories in psychiatryKia Crittenden-Ward, Martina Micaletto, Jennifer Olt, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentTodd Feaster, Prajakta Dinesh Mangeshkar, Siew Tin Gan, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's diseaseEric Siemers, Todd Feaster, Gopalan Sethuraman, et al.
The Journal of Prevention of Alzheimer'S Disease|February 15, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's diseaseErika N Cline, Daniel Antwi-Berko, Karen Sundell, et al.
Pageof 1